tetano
Editor, Senior Moderator
Vaccine
. 2021 Mar 5;S0264-410X(21)00274-7.
doi: 10.1016/j.vaccine.2021.03.006. Online ahead of print.
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
Yingying Du[SUP] 1 [/SUP], Yuhua Xu[SUP] 2 [/SUP], Jin Feng[SUP] 2 [/SUP], Longbo Hu[SUP] 3 [/SUP], Yanan Zhang[SUP] 4 [/SUP], Bo Zhang[SUP] 4 [/SUP], Weili Guo[SUP] 2 [/SUP], Runming Mai[SUP] 2 [/SUP], Liyun Chen[SUP] 2 [/SUP], Jianmin Fang[SUP] 3 [/SUP], Hui Zhang[SUP] 5 [/SUP], Tao Peng[SUP] 6 [/SUP]
Affiliations
Abstract
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.
Keywords: Intranasal administration; Mucosal immunity; Neutralizing antibody; SARS-CoV-2.
. 2021 Mar 5;S0264-410X(21)00274-7.
doi: 10.1016/j.vaccine.2021.03.006. Online ahead of print.
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
Yingying Du[SUP] 1 [/SUP], Yuhua Xu[SUP] 2 [/SUP], Jin Feng[SUP] 2 [/SUP], Longbo Hu[SUP] 3 [/SUP], Yanan Zhang[SUP] 4 [/SUP], Bo Zhang[SUP] 4 [/SUP], Weili Guo[SUP] 2 [/SUP], Runming Mai[SUP] 2 [/SUP], Liyun Chen[SUP] 2 [/SUP], Jianmin Fang[SUP] 3 [/SUP], Hui Zhang[SUP] 5 [/SUP], Tao Peng[SUP] 6 [/SUP]
Affiliations
- PMID: 33731271
- DOI: 10.1016/j.vaccine.2021.03.006
Abstract
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.
Keywords: Intranasal administration; Mucosal immunity; Neutralizing antibody; SARS-CoV-2.